Cargando…
Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial
BACKGROUND: Heterologous boost vaccination has been proposed as an option to elicit stronger and broader, or longer-lasting immunity. We assessed the safety and immunogenicity of heterologous immunization with a recombinant adenovirus type-5-vectored Coronavirus Disease 2019 (COVID-19) vaccine (Conv...
Autores principales: | Jin, Pengfei, Guo, Xiling, Chen, Wei, Ma, Shihua, Pan, Hongxing, Dai, Lianpan, Du, Pan, Wang, Lili, Jin, Lairun, Chen, Yin, Shi, Fengjuan, Liu, Jingxian, Xu, Xiaoyu, Zhang, Yanan, Gao, George F., Chen, Cancan, Feng, Jialu, Li, Jingxin, Zhu, Fengcai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187065/ https://www.ncbi.nlm.nih.gov/pubmed/35617368 http://dx.doi.org/10.1371/journal.pmed.1003953 |
Ejemplares similares
-
Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
por: Li, Jingxin, et al.
Publicado: (2022) -
Preclinical Toxicity and Immunogenicity of a COVID-19 Vaccine (ZF2001) in Cynomolgus Monkeys
por: Yang, Hongzhong, et al.
Publicado: (2022) -
Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial
por: Jin, Lairun, et al.
Publicado: (2022) -
Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants
por: Zhao, Xin, et al.
Publicado: (2021) -
Omicron SARS-CoV-2 Neutralization from Inactivated and ZF2001 Vaccines
por: Zhao, Xin, et al.
Publicado: (2022)